<DOC>
	<DOCNO>NCT01941654</DOCNO>
	<brief_summary>To determine efficacy preemptive local ablative therapy NSCLC patient activate EGFR mutation oligometastatic residual metabolic-active disease first-line EGFR TKI , measure PFS rate 1 year trial enrollment .</brief_summary>
	<brief_title>ATOM_local Ablative Therapy</brief_title>
	<detailed_description />
	<criteria>1 . Pathologically confirm UICC 7th edition Stage IIIB ( amenable curative intent local radiotherapy ) /IV ( metastatic recurrent ) nonsmall cell carcinoma lung 2 . Documented activate EGFR mutation ( exon 19 deletion exon 21 L858R ) tumor tissue 3 . Treated firstline EGFR TKI 3 month achieve good radiological partial response document CT scan 4 . Not 4 residual metabolic active ( SUVmax &gt; 2.5 ) metastatic site leave screen PETCT scan . ( one bone metastatic site regard single site , mediastinal/ hilar lymph node close proximity possible treat acceptable volume regard one lesion ) 5 . The short diameter lesion must ≥ 1cm amenable local ablative therapy 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 7 . Age ≥ 18 year 8 . Pleural pericardial effusion diagnosis allow resolve CT scan 3month EGFR TKI treatment 9 . Brain metastasis diagnosis allow treat either surgically radiotherapy radiological progression followup CT scan . The patient neurologically stable least 1 week cessation steroid treatment 10 . Adequate organ function define follow criterion : 1 . Serum alanine transaminase ≤ 3 x upper limit normal ( ULN ) ≤ 5 x ULN liver function abnormality due liver metastases 2 . Total bilirubin ≤ 1.5 x ULN 3 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L 4 . Platelets count ≥ 100 x 109/L 5 . Creatinine clearance &gt; 45ml/min 11 . Written inform consent consistent ICHGCP guideline 1 . Prior chemotherapy allow except adjuvant chemotherapy completely resect early stag nonsmall cell lung cancer least 12 month start EGFR TKI treatment 2 . Prior radiotherapy allow except brain irradiation 3 . Leptomeningeal carcinomatosis 4 . Lymphangitis carcinomatosis lung 5 . Prior concomitant malignancy site allow except treat nonmetastatic nonmelanoma skin cancer , ductal carcinomainsitu breast carcinomainsitu cervix curative intent 6 . Uncontrolled active infection medical condition ( e.g . uncontrolled hypertension , unstable angina , congestive heart failure [ ≥ NYHA Class II ] , uncontrolled arrhythmia , myocardial infarction cerebrovascular accident within past 6 month ) 7 . Preexisting interstitial lung disease 8 . Woman childbearing potential male patient unwilling use adequate birth control method prior study entry , duration study participation least 2 month EGFR TKI treatment end . 9 . Pregnant Lactating female patient 10 . Noncompliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>